CN107661409A - A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof - Google Patents

A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof Download PDF

Info

Publication number
CN107661409A
CN107661409A CN201711198171.XA CN201711198171A CN107661409A CN 107661409 A CN107661409 A CN 107661409A CN 201711198171 A CN201711198171 A CN 201711198171A CN 107661409 A CN107661409 A CN 107661409A
Authority
CN
China
Prior art keywords
parts
rutin
oral liquid
cerebrovascular disease
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711198171.XA
Other languages
Chinese (zh)
Inventor
付平国
刘文瑞
欧玉莲
王建买
付嫦娥
刘小军
欧召国
付玉香
李凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyang Huashengda Forestry Science And Technology Co Ltd
Original Assignee
Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyang Huashengda Forestry Science And Technology Co Ltd filed Critical Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority to CN201711198171.XA priority Critical patent/CN107661409A/en
Publication of CN107661409A publication Critical patent/CN107661409A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, in terms of weight fraction, including the following raw material：100 parts of rutin, 0.5 2 parts of chlorogenic acid, 0.05 0.10 parts of isatis root extract, 1,000 2000 parts of mineral water, 0.2 0.8 parts of yeast zinc, 0.05 0.10 parts of Stevioside, 0.001 0.005 parts of yeast chromium, 0.5 1 parts of Calyx Seu Fructus Physalis extract, 13 parts of Honegsukle flower P.E.The rutin oral liquid is adapted to：Hypertension, high fat of blood and insomniac, cardiac etc..

Description

A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and its system Preparation Method.
Background technology
Nowadays, cardiovascular and cerebrovascular disease turns into one of three big killers for threatening health of people, due to the side effect ratio of Western medicine It is larger, therefore raising with long-term treatment, Chinese medicine preparation often turns into first choice；Wherein using refined rutin as raw material medicine very Welcome by patient；According to statistics, current China town and country cardiovascular and cerebrovascular diseases occur as 1.2%~1.8%, and the death rate is one thousandth, For national cardiovascular disease number of the infected in 1,600,000 people or so, the occurrence cause of cardiovascular and cerebrovascular diseases is mainly hypertension, high fat of blood；From Rise 54% between 1979~1991,12 years, the age is bigger, the easier generation of cardiovascular and cerebrovascular disease, present China 60 years old with For upper old man more than 1.3 hundred million, China has been enter into aging society；Predicted according to the World Health Organization, the year two thousand twenty whole world 40~60 years old with On population will rise to medical science economy report on October 13rd, more than 1,200,000,000,1997 and the World Health Organization from current 7.4 hundred million In the numeral that on 2 17th, 1997 announce in Geneva；There is within 1994 40% to die from cardiovascular and cerebrovascular disease in whole death tolls Disease.
Rutin product has softening cardiovascular and cerebrovascular, decompression, lipid-loweringing, pre- anti-stroke, and norcholesterol, cholagogic are convenient, promote new The functions such as old metabolism, and capillary toughness can be strengthened, improve cerebrovascular function, it is evident in efficacy for treating hypertension, it is domestic Outer demand is very big；It is medicine-food two-purpose medicinal material as defined in the Ministry of Public Health, develops health food and functional food at home and abroad all has There is wide market, supply falls short of demand always for its high-end product, possesses great development space.
The content of the invention
An object of the present invention is to provide a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, the rutin oral liquid A variety of cardiovascular and cerebrovascular diseases can be treated.
The second object of the present invention is the preparation method for providing above-mentioned rutin oral liquid.
The rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease, in terms of weight fraction, including the following raw material：Rutin 100 Part, chlorogenic acid 0.5-2 parts, isatis root extract 0.05-0.10 parts, yeast zinc 0.2-0.8 parts, Stevioside 0.05-0.10 parts, ferment Female chromium 0.001-0.0005 parts, Calyx Seu Fructus Physalis extract 0.5-1 parts, Honegsukle flower P.E 1-3 parts, mineral water 1000-2000 parts.
Preferably, mineral water is Zhangjiajie mineral water.
Preferably, bauhinia leaf extract can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.1-1 parts.
Preferably, carthamin 0.5-1.0 parts can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease.
Preferably, root of red-rooted salvia phenolic acid 0.005- can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.009 part, preferably root of red-rooted salvia phenolic acid B.
Preferably, Fructus lycii P.E can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.001-0.005 parts and notoginseng total saponin 0.5-1.5 parts.
Preferably, tangshenoside 0.005- can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease 0.009 part.
Preferably, panaquilon 0.005-0.01 can also be added in the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease Part, GL-B 0.005-0.009 parts.
The preparation method of the rutin oral liquid of present invention treatment cardiovascular and cerebrovascular disease, in turn includes the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Stirring 45-60 minutes produce rutin oral liquid in addition mineral water.
Rutin oral liquid of the present invention is precipitated as normal phenomenon, using it is front upper and lower rock corkage it is ready-to-drink；Usage and dosage:Mouthful Clothes, a 10-20ml, 3 times a day.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with example, but those skilled in the art will manage Solution, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.
Mineral water is Zhangjiajie mineral water in embodiment.
Embodiment 1
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g Calyx Seu Fructus Physalis extract 0.5g Honegsukle flower P.Es 1.9g.
Embodiment 2
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9097g.
Embodiment 3
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1570g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g carthamin 0.8g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9097g.
Embodiment 4
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g Calyx Seu Fructus Physalis extract 0.5g Honegsukle flower P.Es 1.9g
Root of red-rooted salvia phenolic acid 7mg.
Embodiment 5
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g carthamin 0.8g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9g root of red-rooted salvia phenolic acid B 7mg.
Embodiment 6
Rutin 80g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1500g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9g Fructus lycii P.Es 3mg.
Notoginseng total saponin 1g.
Embodiment 7
Rutin 100g chlorogenic acid 1.5g isatis root extracts 0.09g
Mineral water 1400g yeast zinc 0.3g Steviosides 0.06g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Calyx Seu Fructus Physalis extracts 0.7g
Honegsukle flower P.E 1.9g Fructus lycii P.E 4mg notoginseng total saponins 0.9g.
Embodiment 8
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1380g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9097g tangshenosides 7mg panaquilon's 7mg GL-Bs 6mg.
Embodiment 9
Rutin 100g chlorogenic acid 1.1g isatis root extracts 0.05g
Mineral water 1500g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Calyx Seu Fructus Physalis extracts 0.6g
Honegsukle flower P.E 1.8g tangshenosides 9mg panaquilon's 6mg GL-Bs 5mg.
Embodiment 10
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1300g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Calyx Seu Fructus Physalis extracts 0.5g
Honegsukle flower P.E 1.9g root of red-rooted salvia phenolic acid B 8mg tangshenoside 7mg
Fructus lycii P.E 6mg notoginseng total saponins 7mg.
Embodiment 11
Rutin 100g chlorogenic acid 1.2g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g Steviosides 0.08g
Yeast chromium 0.005g bauhinia leaf extract 0.4g Calyx Seu Fructus Physalis extracts 0.6g
Honegsukle flower P.E 1.7g root of red-rooted salvia phenolic acid B 6mg tangshenoside 6mg
Fructus lycii P.E 8mg notoginseng total saponins 7mg.
The preparation method of the rutin oral liquid of above example comprises the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Add in mineral water to stir 60 minutes and produce rutin oral liquid.
Rutin oral liquid clinical effectiveness of the embodiment of the present invention is as follows：
Experimental method：
A groups:Hypertensive patient 110, it is divided into 11 groups, every group of 10 people, every group of patient takes embodiment 1-11 rutin mouth respectively Liquid is taken, 3 times a day, each 10mL, 40 minutes warm boiled waters before meals, 30 days are 1 course for the treatment of, take 5 courses for the treatment of.
B groups：Thrombolysis contrasts, and patient 120 is divided into 12 groups, every group of 10 people, every group of rutin for taking embodiment 1-11 respectively Oral liquid, western drug treatment（Control group）, 3 times a day, each 20mL, 40 minutes warm boiled waters, are 1 in 30 days and treat before meals Journey, two groups of patients are in age, sex, thrombosis position, the course of disease, clinical manifestation etc. comparing difference without conspicuousness.
Experimental result：
A groups:The preceding patient's diastolic pressure of medication is more than 180mmHg, and systolic pressure is more than 110mmHg, main suit's giddy, tinnitus, uncomfortable in chest, gas Short, insomnia, head Doppler show that blood vessel has Partial Blocking；After taking 5 courses for the treatment of, blood pressure tends to be steady, and lives and recovers completely.
That takes hypertensive patient after 5 courses for the treatment of the results are shown in Table 1.
The hypertensive patient of table 1 takes the therapeutic effect of rutin oral liquid
。
B groups：The evaluated order of severity of thrombosis patients is suitable before medication, and patient is in age, sex, thrombosis position, disease Journey, clinical manifestation etc. comparing difference are without conspicuousness；Medicine of the present invention, without complication, has no haemorrhage during thrombolysis Shape, occasionally there is patient slight gastrointestinal reaction occur, disappeared after giving anti symptom treatment.
The experimental result of thrombosis patients is shown in Table 25 after taking 45 days.
Table 2
。
As can be seen from Table 5, rutin oral liquid treatment group is evident in efficacy is higher than western medicine group, and rutin oral liquid thrombolysis is A kind of safely and effectively method.
Model case：Mr. Li, original angina pectoris and sinus standstill, V5T popins are smooth, take 11 oral liquid of embodiment 5 After the course for the treatment of, T ripples are back to normally, and sinus standstill disappears.
Above content describes the general principle and principal character of the present invention, and the present invention is not limited to the above embodiments, Without departing from the spirit and scope of the present invention, various changes and modifications of the present invention are possible, and these changes and improvements are all Fall into scope of the claimed invention.

Claims (10)

1. a kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease, in terms of parts by weight, including the following raw material：100 parts of rutin, it is green Ortho acid 0.5-2 parts, isatis root extract 0.05-0.10 parts, yeast zinc 0.2-0.8 parts, Stevioside 0.05-0.10 parts, yeast chromium 0.001-0.005 parts, Calyx Seu Fructus Physalis extract 0.5-1 parts, Honegsukle flower P.E 1-3 parts, mineral water 1000-2000 parts.
2. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that described rutin is ore deposit Spring is Zhangjiajie mineral water.
3. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add cercis Floral leaf extract 0.1-1 parts.
4. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add safflower Glucoside 0.5-1.0 parts.
5. according to the rutin oral liquid of the treatment cardiovascular and cerebrovascular disease of claim 1 or 4, it is characterised in that pellet can also be added Join phenolic acid 0.005-0.009 parts.
6. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that described root of red-rooted salvia phenolic acid For root of red-rooted salvia phenolic acid B.
7. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add matrimony vine Seed extract 0.001-0.005 parts and notoginseng total saponin 0.5-1.5 parts.
8. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add Radix Codonopsis Glucoside 0.005-0.009 parts.
9. the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that can also add ginseng Glucoside 0.005-0.01 parts, GL-B 0.005-0.009 parts.
10. the preparation method of the rutin oral liquid of cardiovascular and cerebrovascular disease is treated according to claim 1, it is characterised in that successively Comprise the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Stirring 45-60 minutes produce rutin oral liquid in addition mineral water.
CN201711198171.XA 2017-11-25 2017-11-25 A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof Pending CN107661409A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711198171.XA CN107661409A (en) 2017-11-25 2017-11-25 A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711198171.XA CN107661409A (en) 2017-11-25 2017-11-25 A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107661409A true CN107661409A (en) 2018-02-06

Family

ID=61145296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711198171.XA Pending CN107661409A (en) 2017-11-25 2017-11-25 A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107661409A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113143962A (en) * 2021-05-11 2021-07-23 四川九章生物科技有限公司 A pharmaceutical composition for treating hyperlipidemia, and its preparation method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田洋: "槐米中芦丁的提取工艺研究进展", 《广州化工》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113143962A (en) * 2021-05-11 2021-07-23 四川九章生物科技有限公司 A pharmaceutical composition for treating hyperlipidemia, and its preparation method

Similar Documents

Publication Publication Date Title
CN103877263B (en) A kind of antifatigue health preparation of the compound Chinese medicine such as red ginseng, maca, green-tea extract (theanine)
CN102698137B (en) Composition with blood pressure reducing function and preparation method of same
CN106214846A (en) Moringa preparation of fat and preparation method and application is adjusted in nourishing the liver
CN103251814A (en) Traditional Chinese medicine preparation for adjusting hypertension, hyperlipemia and hyperglycemia
CN101467673A (en) Compound ginseng health product and preparation method thereof
CN104147345B (en) A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy
CN107661409A (en) A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof
CN103977390B (en) A kind of preparation method and its usage of ginger onion medicated wine composition
CN102068520B (en) Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN102178792B (en) Shiqi exogenous Chinese medicinal buccal tablets
CN108079119A (en) Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof
CN103845526A (en) Traditional Chinese medicine tea drink for treating hypertension associated with diabetes
CN107753645A (en) Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof
CN107854567A (en) A kind of Quercetin traditional Chinese medicine oral liquid and preparation method thereof
CN102805799A (en) Traditional Chinese medicine composition with antitumous effect
CN103013806A (en) Health-care therapeutic herbal vinegar
CN103525640B (en) Energy-keeping yang-tonifying wine
CN102274357B (en) Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof
CN102266481B (en) Chinese medicinal preparation for treating chronic cerebral circulation insufficiency
CN101612251B (en) Traditional Chinese medicine for treating primary liver cancer
CN102552677B (en) Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof
CN102293296B (en) Blood-pressure-reducing anticancer tea
CN104173745A (en) Nourishing and body-building Mongolian medicine
CN103191267A (en) Traditional Chinese medicine composition for treating liver cancers
CN102772665B (en) Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180206

WD01 Invention patent application deemed withdrawn after publication